Coming Soon: PeriRx LLC’s Breakthrough Salivary Test to Aid in the Fight Against Oral Cancer
-->
The World’s
Most Clinically Advanced and Scientifically Validated Molecular DNA Biomarker Test
for Oral Squamous Cell Carcinoma is Launching in Late Spring
Havertown,
PA – April 3, 2014 – PeriRx LLC, a premier developer of breakthrough,
non-invasive, oral diagnostic technology recently announced that it will be
introducing the world’s most
clinically advanced and scientifically validated molecular DNA biomarker test
for oral squamous cell carcinoma detection in the late spring.
According
to PeriRx LLC’s CEO Stephen M. Swanick, “This is a simple-to-use, painless and
noninvasive test designed for front line healthcare practitioners that enables them
to detect disease earlier, enhance patient wellness and reduce the overall cost
of healthcare.”
.
The
salivary test is based on a strong scientific foundation of NIH-funded research
with initial discovery and pre-validation work by Dr. David Wong of the
University of California at Los Angeles. The test also has the distinction of
being the first of its kind assay in the world to aid in the identification and
early detection of oral lesions at the highest risk for cancer.
These
discriminatory salivary biomarkers have been clinically validated in multiple
large trials including studies in collaboration with the National Cancer
Institute and with premiere US academic medical centers
such as the University of Michigan, Michigan
State University and the Providence Health System in Detroit.
For more information, visit www.PeriRx.com.
To become an early adopter of the salivary test, or to become an investor in
PeriRx LLC, contact Stephen M. Swanick at 610-449-9625 or perirx@rcn.com.
About PeriRx LLC:
Based in Havertown, Pennsylvania, PeriRx LLC is a
premier developer of breakthrough, non-invasive, oral diagnostic technology
that will help clinical professionals
detect and treat diseases sooner and enhance the practice of wellness management.
The company was founded
in 2008 to explore, innovate, and develop novel therapeutics or devices focused
on the oral inflammatory/systemic connection. The PeriRx executive team
consists of CEO Stephen M. Swanick, an entrepreneur and experienced drug and
device development professional; Dr. Neil Gottehrer, a practicing dentist; and
Dr. Jack Martin, a cardiologist.
PeriRx obtained its
patented and patent-pending technologies from inventor Dr. David Wong’s firm
RNAmeTRIX and the Regents of the University of California at Los Angeles.
PeriRx and RNAmeTrix have ongoing agreements which ensure the continuing
research and development necessary to advance product development from clinical
trial, through FDA approval, and into commercialization.
# # #
Comments